| Nom de la société: | FTSEurofirst 300 Pharmaceuticals and Biotechnology Index |
| EPIC: | E3X201030 | Trading Currency: | GBP |
| Market Sector: | | ISIN: | |
| Market Segment: | | Share Type: | IX |
| WWW Address: | | Description: | |
| Secteur Industriel: | |
| Prix | Prix chgmt [%] | Achat | Vente | Ouverture | High | + Bas | Volume |
| 3,039.35 |  0.0 [0.00] | - | - | 3,039.35 | 3,039.35 | 3,039.35 | - |
| Market Cap. [m] | Shares In Issue [m] | Beta | EPS | DPS | PE Ratio | Yield | 52-Wks-Range |
| - | - | - | - | - | - | - | 3,526.94 - 2,726.57 |
CHIFFRES CLES - fermeture de la veille| CHIFFRES CLES - fermeture de la veille | | (at previous day's close) |
| Market Cap. | - | m |
| Shares In Issue | - | m |
| Prev. Close | 3,039.35 | |
| PE Ratio | - | |
| Taux de rendement des actions | - | % |
| EPS - basic | - | p |
| Dividend PS | - | p |
| Dividend Cover | - | |
| Cash Flow PA | - | p |
| Rentabilité des capitaux propres (ROE) | - | % |
| Excedent Brut D'exploitation | - | % |
| PEG Factor | - | |
| BNA Taux de croissance | - | % |
| Dividendes PA Taux de Croissance | - | % |
| Endettement Net | - | m |
| Gearing Brut | - | % |
| Avoirs liquides | - | m |
| Fonds de roulement Nets | - | m |
| Incorporels / Actifs immobilisés | - | % |
| Turnover PS | - | p |
| Pre-Tax Profit PS | - | p |
| Retained Profit PS | - | p |
| Cash pA | - | p |
| Cash net PA | - | p |
| Net Tangible Asset Value PS * | - | p |
| Net Asset Value PS | - | p |
| Écart de Taux | - (-%) | |
| * Calculation based on Ordinary Capital figure as contained in last annual report, and the most recent shares in issue figure. Therefore the ratio might be exposed to inaccuracies. |
|
Bilan (en résumé)| Bilan (en résumé) | | Sorry No Data Available |
|
Performance de l'action| Performance de l'action | | Sample Period † | High | + Bas | | 1 sem. | 3,065.21 | 2,953.31 |
| 4 Semaines | 3,201.00 | 2,920.26 |
| 12 Semaines | 3,491.90 | 2,920.26 |
| 1 an | 3,526.94 | 2,726.57 |
Performance de l'action - 5 dernieres années| Performance de l'action - 5 dernieres années |  |
|
FTSEurofirst 300 Pharmac... Historic Returns| %1$s Historic Returns | | Période † | Ouverture | Chg à ce jour | % | Moy. Ouvert. | Vol moyen / jour [m] | Total Vol [m] | VWAP | | 1 sem. | 2,953.31 | 86.04 | 2.91 | 2,953.31 | - | | - |
| 4 Semaines | 3,201.00 | -161.65 | -5.05 | 2,920.26 | - | | - |
| 12 Semaines | 3,490.51 | -451.16 | -12.93 | 2,920.26 | - | | - |
| 26 Semaines | 3,167.88 | -128.53 | -4.06 | 2,920.26 | - | | - |
| 1 an | 2,803.87 | 235.48 | 8.40 | 2,726.57 | - | | - |
| 3 Années | 2,549.95 | 489.40 | 19.19 | 2,457.70 | - | | - |
| 5 Années | 90.23 | 2,949.12 | 3,268.45 | 90.23 | - | | - |
| † periods calculated are whole weeks rather than calendar months | |
|
FTSEurofirst 300 Pharmac... Key Management Ratios
|
FTSEurofirst 300 Pharmac... Investment Ratios| %1$s Investment Ratios | | (Market value analysis) at previous day's close |
| PQ Ratio | - | |
| PE Ratio | - | |
| Tobin's Q Ratio | - | |
| Tobin's Q Ratio (excl. intangibles) | - | |
| Taux de rendement des actions | - | % |
| Market-to-Book Ratio | - | |
| Price-to-Pre-Tax Profit PS | - | |
| Price-to-Retained Profit PS | - | |
| Price-to-Cash Flow PS | - | |
| Price-to-Sales PS | - | |
| Price-to-Net Tangible Asset Value PS | - | |
| Price-to-Cash PS | - | |
| Net Working Capital PS | - | |
| Price Pct to Working Capital PS | - | % |
| Earnings Yield | - | % |
| Average PE | - | |
| Years in average | - | |
| PE to PE average | - | % |
|
Ratios Financiers| Ratios Financiers | | (Ratios de Levier) |
| Ratio d'endettement | - | % |
| Ratio Dettes/ Fond Propres | - | |
| Ratio Dettes/ Fond Propres (excl Incorp) | - | |
| Valeur du Marché - Dettes/ Fond Propres | - | |
| Gearing Net | - | % |
| Gearing Net (excl. Intangibles) | - | % |
| Gearing Brut | - | % |
| Gearing Brut (excl. Intangibles) | - | % |
| Gearing moins d'un an | - | % |
| Gearing moins d'un an (excl Intangibles) | - | % |
| Actifs / Capitaux propres | - | |
| Cash/Capitaux propres | - | |
| (Liquidité ratios) |
| Fonds de roulement Nets - Total Actifs | - | % |
| Ratio de Liquidité Generale | - | |
| Ratio de liquidité immédiate (Acid Test) | - | |
| Ratio de Liquidité | - | |
| Cash et Equiv/ Actifs circulants | - | % |
| Solvabilité ratios |
| Enterprise Value | - | m |
| CFO/Sales | - | |
| CFO/Attributable Profit | - | |
| CFO/Actifs | - | |
| CFO/Debt | - | |
| Total Dettes/ capitaux propres Valeur du marché | - | |
| Total Dettes/Ventes | - | |
| Total Dettes/ Profit avant imposition | - | |
| Total Debt | - | m |
| Total Debt/Net Current Assets | - | % |
| (Dodds - Graham Ratios) | | |
| 3 yr Compound Earnings Growth | - | % |
| 5 yr Compound Earnings Growth | - | % |
| 10 yr Compound Earnings Growth | - | % |
| Earn drops > 5% in 10yrs | - | |
| Beta coefficients | | Beta (60 mois) | Beta (36mois) | | Sorry No Data Available | Sorry No Data Available |
|
Ratios Operationnels| Ratios Operationnels | | Ratio de Rentabilité) |
| Rentabilité des capitaux investis | - | % |
| Rentabilité Des Actifs (ROA) | - | % |
| Marge Beneficiaire Nette | - | % |
| Assets Turnover | - | |
| Rentabilité des capitaux propres (ROE) | - | % |
| Retour sur investissement | - | % |
| Ratio de distribution des dividendes | - | % |
| Plowback Ratio | 100.00 | % |
| Growth from Plowback Ratio | - | % |
| Net Income Of Revenues | - | % |
| (Asset Utilisation Multiples) |
| Chiffres d'affaires Fonds Propres | - | |
| Fixed Assets Turnover | - | |
| Current Assets Turnover | - | |
| Chiffre d'affaires Fonds de roulement Nets | | |
| Inventory Turnover | - | |
| (Autres Ratios Operationnels) |
| Total Assets-to-Sales | - | |
| Debtors-to-Sales | - | % |
| Debt Collection Period | - | Jours |
|
Dividendes
|
|
FTSEurofirst 300 Pharmac... Fondamentaux |
|
|
Bilan (en résumé)
|
FTSEurofirst 300 Pharmac... Cash Flow Statement
| FTSEurofirst 300 Pharmac... Brokers| Broker infomation is not available for this class of stock. |
| | | | | | | | |
|
|
|
